Status:
TERMINATED
Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus
Lead Sponsor:
Merz Pharmaceuticals GmbH
Conditions:
Nystagmus, Congenital
Nystagmus, Acquired
Eligibility:
All Genders
18-81 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of...
Eligibility Criteria
Inclusion
- patients who has succesfully completed the lead-in study MRZ 92579-0707/1
Exclusion
- Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00799942
Start Date
May 1 2009
Last Update
July 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group
Leicester, United Kingdom, LE2 7LX